This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Calgary directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $2,796,075
A Phase I Feasibility and Safety Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Relapsed/Refractory GPNMB-Expressing Solid Tumors
CIHR · 2023 · Principal investigator
A Phase I Feasibility and Safety Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Relapsed/Refractory GPNMB-Expressing Solid Tumors
Principal investigators: Shafey, Mona; Abdul Razak, Albiruni R; Hay, Kevin A; Henning, Jan-Willem; Kekre, Natasha; Mahoney, Douglas J; Morrissy, Sorana A; Noujaim, Jonathan; Simmons, Christine E
Keywords: Alveolar Soft Part Sarcoma; Car T; Immunotherapy; Renal Cell Carcinoma; Sarcoma; Triple-Negative Breast Cancer
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.